Article Sidebar

pdf
Date Published: 20/12/2024
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v545i2.12217
Issue
Vol. 545 No. 2 (2024)
Section
Các bài báo
How to Cite
Lê, T. H., Phạm, T. M. C., Phạm, T. T. T., & Nguyễn, B. V. (2024). ASSESSMENT OF EARLY TREATMENT RESULTS FOR BILATERAL GROUP E RETINOBLASTOMA USING A COMBINED APPROACH OF SYSTEMIC CHEMOTHERAPY AND LOCAL OCULAR THERAPY. Vietnam Medical Journal, 545(2). https://doi.org/10.51298/vmj.v545i2.12217

ASSESSMENT OF EARLY TREATMENT RESULTS FOR BILATERAL GROUP E RETINOBLASTOMA USING A COMBINED APPROACH OF SYSTEMIC CHEMOTHERAPY AND LOCAL OCULAR THERAPY

Thị Hương Lê, Thị Minh Châu Phạm, Thị Thu Thủy1 Phạm, Bá Việt Nguyễn

Main Article Content

Abstract

Objective: To evaluate the initial results of systemic chemotherapy combined with local treatment for bilateral retinoblastoma (RB) Group E. Method: A prospective descriptive case series study involving 8 patients diagnosed with bilateral Group E retinoblastoma treated with systemic chemotherapy combined with local therapy at the Viet Nam National Eyes Hospital from August 2023 to August 2024. Results: The study involved 8 patients with intraocular bilateral retinoblastoma, encompassing 9 eyes classified as Group E. Patient characteristics revealed that leukocoria was the most common symptom, and most patients had a healthy personal and family medical history. Follow-up and treatment outcomes for Group E retinoblastoma indicated that all tumors reduced in size, with an average decrease of 4.3 mm. Six eyes showed a good response to treatment, while 3 cases did not respond and required enucleation. Conclusion: The combination of systemic chemotherapy and local treatment (laser/cyrotherapy) is necessary and safe for managing intraocular retinoblastoma, aiming to reduce tumor size, preserve vision, and limit enucleation.

Article Details

Keywords

retinoblastoma Group E, limit enucleation.

References

eregard S., Lundell G., Svedberg H., Kivelä T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology. Jun 2004. 111(6):1228-1232.
2. MacCarthy A., Birch J. M., Draper G. J., et al. Retinoblastoma in Great Britain 1963-2002. The British journal of ophthalmology. Jan 2009. 93(1):33-37.
3. Shields CL, et al. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol. 2020 Nov;104(11):1548-1555.
4. Jain, M., et al., Retinoblastoma in Asia. Eye (Lond), 2019. 33(1): p. 87-96.
5. Bakal K, Raval V, Gattu SK, Palkonda VAR, Kaliki S. Primary Subretinal Seeding in Retinoblastoma: Clinical Presentation and Treatment Outcomes. Ocul Oncol Pathol. 2023 Aug;9(1-2):32-39.
6. Gombos, D.S., et al., Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location, and age. Br J Ophthalmol, 2002. 86(1): p. 80-3.